MedTrace Logo

Study to Assess the Feasibility in Bile cfDNA of Resectable Biliary Tract Carcinomas

NCT05783973 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-05-30

No results posted yet for this study

Summary

This study intends to use Onconscreen plus 520 Panel (Burning Rock, China) to conduct NGS testing in matched tissue, blood , and bile samples of patients with Resectable Biliary Tract Carcinomas（BTC）. In order to explore thefeasibility in bile cfDNA of BTC，we will collect relevant clinical information and follow-up treatment information. This study aims to reveal the effectiveness, accuracy, and feasibility in bile, as compared to tissues and blood samples.

Conditions

  • This Study Aims to Reveal the Effectiveness, Accuracy, and Feasibility in Bile

Interventions

DIAGNOSTIC_TEST

Next generation sequencing

Extract DNA from bile，tissue and tissue sample, minimum DNA amount should be over 50ng.

Sponsors & Collaborators

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Changzhen Shang, MD · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-02
Primary Completion
2023-12-31
Completion
2024-02-02

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05783973 on ClinicalTrials.gov